Get started
Glaukos CorporationGlaukos CorporationGlaukos Corporation

Glaukos Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

GKOS chart


Full chart

GKOS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪7.24 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.20 USD
Net income (FY)
‪−134.66 M‬ USD
Revenue (FY)
‪314.71 M‬ USD
Shares float
‪52.95 M‬
Beta (1Y)
0.68

Employees


Employees (FY)
907
Change (1Y)
+124 +15.84%
Revenue / Employee (1Y)
‪346.98 K‬ USD
Net income / Employee (1Y)
‪−148.47 K‬ USD

About Glaukos Corporation


Sector
Health Technology
Industry
Medical Specialties
CEO
Thomas William Burns
Website
glaukos.com
Headquarters
Aliso Viejo
Founded
1998
FIGI
BBG000WG2LQ1
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GKOS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GKOS highest yielding bonds


GKOS5209614
Glaukos Corporation 2.75% 15-JUN-2027
Yield to maturity
−29.46%
Maturity date
Jun 15, 2027

Explore more bonds 

Frequently Asked Questions


The current price of GKOS is 131.38 USD — it has decreased by −0.30% in the past 24 hours. Watch Glaukos Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Glaukos Corporation stocks are traded under the ticker GKOS.
GKOS stock has fallen by −0.27% compared to the previous week, the month change is a 1.96% rise, over the last year Glaukos Corporation has showed a 100.73% increase.
We've gathered analysts' opinions on Glaukos Corporation future price: according to them, GKOS price has a max estimate of 155.00 USD and a min estimate of 115.00 USD. Watch GKOS chart and read a more detailed Glaukos Corporation stock forecast: see what analysts think of Glaukos Corporation and suggest that you do with its stocks.
GKOS reached its all-time high on Oct 30, 2024 with the price of 139.51 USD, and its all-time low was 14.25 USD and was reached on Feb 8, 2016. View more price dynamics on GKOS chart.
See other stocks reaching their highest and lowest prices.
GKOS stock is 3.73% volatile and has beta coefficient of 0.68. Track Glaukos Corporation stock price on the chart and check out the list of the most volatile stocks — is Glaukos Corporation there?
Today Glaukos Corporation has the market capitalization of ‪7.22 B‬, it has increased by 6.29% over the last week.
Yes, you can track Glaukos Corporation financials in yearly and quarterly reports right on TradingView.
Glaukos Corporation is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GKOS earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.48 USD resulting in a 41.39% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about Glaukos Corporation earnings.
Glaukos Corporation revenue for the last quarter amounts to ‪96.67 M‬ USD, despite the estimated figure of ‪91.50 M‬ USD. In the next quarter, revenue is expected to reach ‪100.22 M‬ USD.
GKOS net income for the last quarter is ‪−50.55 M‬ USD, while the quarter before that showed ‪−40.84 M‬ USD of net income which accounts for −23.77% change. Track more Glaukos Corporation financial stats to get the full picture.
No, GKOS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 907.00 employees. See our rating of the largest employees — is Glaukos Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Glaukos Corporation EBITDA is ‪−76.22 M‬ USD, and current EBITDA margin is −27.24%. See more stats in Glaukos Corporation financial statements.
Like other stocks, GKOS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Glaukos Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Glaukos Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Glaukos Corporation stock shows the buy signal. See more of Glaukos Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.